CG
DFTX

Cutler Group’s Definium Therapeutics DFTX Stock Holding History

Cutler Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27,500
Closed -$67K – 4354
2022
Q4 		$67K Sell
27,500
-700
-2% -$1.94K 0.01% 1395
2022
Q3 		$63K Buy
28,200
+26,387
+1,455% +$253K ﹤0.01% 1740
2022
Q2 		$52K Sell
1,813
-160
-8% -$2.02K ﹤0.01% 1922
2022
Q1 		$48K Sell
1,973
-514
-21% -$8.92K ﹤0.01% 2280
2021
Q4 		$55K Sell
2,487
-266
-10% -$8.49K ﹤0.01% 2332
2021
Q3 		$37K Sell
2,753
-1,007
-27% -$43.5K ﹤0.01% 2777
2021
Q2 		$67K Buy
+3,760
New +$197K ﹤0.01% 2230

Other funds holding DFTX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cutler Group's DFTX Position: Q1 2024 in Review

Cutler Group increased its Definium Therapeutics (DFTX) stake by 133% in Q1 2024, buying an estimated $975 and bringing the position to 300 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Cutler Group first reported a position in DFTX in Q2 2021 and has held it in 12 quarters since. The position peaked at $72K in Q3 2021. 135 funds tracked by Wall St. Rank hold DFTX as of Q1 2024.

  • Cutler Group held 300 shares of Definium Therapeutics worth $2K as of Q1 2024.
  • Cutler Group bought 171 Definium Therapeutics shares in Q1 2024, an estimated $975.
  • Definium Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1868 holding.
  • Cutler Group first reported a position in Definium Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • Cutler Group's Definium Therapeutics position peaked at $72K in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.